Browsing Clinical Studies by author "Popat, Sanjay"
Now showing items 1-20 of 40
-
Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.
Juan, O; Popat, S (2017-11)The oligometastatic state represents a distinct entity among those with metastatic disease and consists of patients with metastases limited in number and location, representing an intermediate state between locally confined ... -
Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.
Dolly, SO; Collins, DC; Sundar, R; Popat, S; Yap, TA (2017-05)Non-small-cell lung cancer (NSCLC) remains a significant global health challenge and the leading cause of cancer-related mortality. The traditional 'one-size-fits-all' treatment approach has now evolved into one that ... -
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
Camidge, DR; Kim, HR; Ahn, M-J; Yang, JC-H; Han, J-Y; Lee, J-S; Hochmair, MJ; Li, JY-C; Chang, G-C; Lee, KH; Gridelli, C; Delmonte, A; Garcia Campelo, R; Kim, D-W; Bearz, A; Griesinger, F; Morabito, A; Felip, E; Califano, R; Ghosh, S; Spira, A; Gettinger, SN; Tiseo, M; Gupta, N; Haney, J; Kerstein, D; Popat, S (2018-11)<h4>Background</h4>Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has robust efficacy in patients with ALK-positive non-small-cell lung cancer (NSCLC) that is refractory to crizotinib. The efficacy ... -
Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions.
Puglisi, M; Stewart, A; Thavasu, P; Frow, M; Carreira, S; Minchom, A; Punwani, R; Bhosle, J; Popat, S; Ratoff, J; de Bono, J; Yap, TA; O''Brien, M; Banerji, U (2016-01)<h4>Objectives</h4>We hypothesised that it was possible to quantify phosphorylation of important nodes in the phosphatidylinositol 3-kinase (PI3K) pathway in cancer cells isolated from pleural effusions of patients with ... -
Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.
Papadatos-Pastos, D; Roda, D; De Miguel Luken, MJ; Petruckevitch, A; Jalil, A; Capelan, M; Michalarea, V; Lima, J; Diamantis, N; Bhosle, J; Molife, LR; Banerji, U; de Bono, JS; Popat, S; O'Brien, MER; Yap, TA (2017-04)<h4>Background</h4>We have previously reported a prognostic score for patients in phase I trials in the Drug Development Unit, treated at the Royal Marsden Hospital (RPS). The RPS is an objective tool used in patient ... -
COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.
Crabb, SJ; Martin, K; Abab, J; Ratcliffe, I; Thornton, R; Lineton, B; Ellis, M; Moody, R; Stanton, L; Galanopoulou, A; Maishman, T; Geldart, T; Bayne, M; Davies, J; Lamb, C; Popat, S; Joffe, JK; Nutting, C; Chester, J; Hartley, A; Thomas, G; Ottensmeier, C; Huddart, R; King, E (2017-12)<h4>Background</h4>Cisplatin is one of the most ototoxic chemotherapy drugs, resulting in a permanent and irreversible hearing loss in up to 50% of patients. Cisplatin and gentamicin are thought to damage hearing through ... -
Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer.
Yap, TA; Macklin-Doherty, A; Popat, S (2017-01)The majority of patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) respond to first-line EGFR tyrosine kinase inhibitors (TKIs), but nearly all inevitably acquire resistance and ... -
Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients.
Juan, O; Popat, S (2017-02) -
Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?
Reck, M; Kerr, KM; Grohé, C; Manegold, C; Pavlakis, N; Paz-Ares, L; Huber, RM; Popat, S; Thatcher, N; Park, K; Hilberg, F; Barrueco, J; Kaiser, R (2019-04)A substantial proportion of patients with nononcogene-addicted non-small-cell lung cancer (NSCLC) has 'aggressive disease', as reflected in short time to progression or lack of disease control with initial platinum-based ... -
Development of molecularly targeted agents and immunotherapies in small cell lung cancer.
Sharp, A; Bhosle, J; Abdelraouf, F; Popat, S; O'Brien, M; Yap, TA (2016-06)Small cell lung cancer (SCLC) is a smoking-induced malignancy with multiple toxin-associated mutations, which accounts for 15% of all lung cancers. It remains a clinical challenge with a rapid doubling time, early dissemination ... -
Do Statins Improve Survival in Small-Cell Lung Cancer?
Popat, S (2017-05) -
Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach.
Pender, A; Garcia-Murillas, I; Rana, S; Cutts, RJ; Kelly, G; Fenwick, K; Kozarewa, I; Gonzalez de Castro, D; Bhosle, J; O'Brien, M; Turner, NC; Popat, S; Downward, J (2015-01)Droplet digital PCR (ddPCR) can be used to detect low frequency mutations in oncogene-driven lung cancer. The range of KRAS point mutations observed in NSCLC necessitates a multiplex approach to efficient mutation detection ... -
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.
Rosell, R; Dafni, U; Felip, E; Curioni-Fontecedro, A; Gautschi, O; Peters, S; Massutí, B; Palmero, R; Aix, SP; Carcereny, E; Früh, M; Pless, M; Popat, S; Kotsakis, A; Cuffe, S; Bidoli, P; Favaretto, A; Froesch, P; Reguart, N; Puente, J; Coate, L; Barlesi, F; Rauch, D; Thomas, M; Camps, C; Gómez-Codina, J; Majem, M; Porta, R; Shah, R; Hanrahan, E; Kammler, R; Ruepp, B; Rabaglio, M; Kassapian, M; Karachaliou, N; Tam, R; Shames, DS; Molina-Vila, MA; Stahel, RA; BELIEF collaborative group (2017-05)<h4>Background</h4>The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutations. The coexistence ... -
An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach.
Melosky, B; Popat, S; Gandara, DR (2018-01)The optimal treatment sequence for patients with metastatic epidermal growth factor receptor (EGFR) mutation-positive (EGFR-M<sup>+</sup>) non-small-cell lung cancer (NSCLC) continues to evolve, related largely to an ... -
First-line Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors for EGFR Mutant Non-small Cell Lung Cancer: And the Winner is….
Juan, O; Yousaf, N; Popat, S (2017-01) -
High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.
Pearson, A; Smyth, E; Babina, IS; Herrera-Abreu, MT; Tarazona, N; Peckitt, C; Kilgour, E; Smith, NR; Geh, C; Rooney, C; Cutts, R; Campbell, J; Ning, J; Fenwick, K; Swain, A; Brown, G; Chua, S; Thomas, A; Johnston, SRD; Ajaz, M; Sumpter, K; Gillbanks, A; Watkins, D; Chau, I; Popat, S; Cunningham, D; Turner, NC (2016-08)<h4>Unlabelled</h4>FGFR1 and FGFR2 are amplified in many tumor types, yet what determines response to FGFR inhibition in amplified cancers is unknown. In a translational clinical trial, we show that gastric cancers with ... -
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
Mazieres, J; Drilon, A; Lusque, A; Mhanna, L; Cortot, AB; Mezquita, L; Thai, AA; Mascaux, C; Couraud, S; Veillon, R; Van den Heuvel, M; Neal, J; Peled, N; Früh, M; Ng, TL; Gounant, V; Popat, S; Diebold, J; Sabari, J; Zhu, VW; Rothschild, SI; Bironzo, P; Martinez-Marti, A; Curioni-Fontecedro, A; Rosell, R; Lattuca-Truc, M; Wiesweg, M; Besse, B; Solomon, B; Barlesi, F; Schouten, RD; Wakelee, H; Camidge, DR; Zalcman, G; Novello, S; Ou, SI; Milia, J; Gautschi, O (2019-08)<h4>Background</h4>Anti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely used to treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of ICI across NSCLC harboring oncogenic alterations ... -
Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer.
Tokaca, N; Wotherspoon, A; Nicholson, AG; Fotiadis, N; Thompson, L; Popat, S (2017-09)Small cell transformation is a rare but well recognised mechanism of acquired resistance to EGFR-TKI therapy in EGFR-mutated NSCLC, but optimal drug therapy thereof is unknown. Nivolumab has demonstrated activity in relapsed ... -
LUME-Meso Phase II/III Study: Nintedanib plus Pemetrexed/Cisplatin in Chemo-Naive Patients with Malignant Pleural Mesothelioma
Scagliotti, G; Gaafar, R; Nowak, A; Tsao, A; Vogelzang, N; Kuribayashi, K; Velema, D; Morsli, N; Popat, S (ELSEVIER SCIENCE INC, 2017-11-01) -
LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.
Scagliotti, GV; Gaafar, R; Nowak, AK; Reck, M; Tsao, AS; van Meerbeeck, J; Vogelzang, NJ; Nakano, T; von Wangenheim, U; Velema, D; Morsli, N; Popat, S (2017-09)Malignant pleural mesothelioma (MPM) is a rare but aggressive disease: median survival is 6 to 9 months if untreated. Standard first-line treatment for patients with unresectable MPM is cisplatin/pemetrexed, with a median ...